Descripción de la empresa
PROCEPT BioRobotics Corporation operates as a specialized surgical robotics firm focused on developing transformative solutions within the urology sector both domestically and internationally. The company's core business involves the development, manufacturing, and commercialization of the AquaBeam Robotic System, which serves as an image-guided, surgical robotic platform designed specifically for minimally invasive urologic procedures. As a key participant in the healthcare sector, this industry classification identifies the firm within the broader medical devices landscape, where innovation in precision instrumentation drives market demand. The entity demonstrates a significant market presence with a total market capitalization of $1.41 billion and generates annual revenue of $308.05 million, supported by a workforce of 888 employees. These valuation and revenue metrics indicate that the company has secured a substantial position in its niche, reflecting strong market confidence despite the capital-intensive nature of developing advanced robotic surgical technologies.
Salud financiera
The company reported trailing twelve-month revenue of $308.05 million, yet recorded a net income of -$95,572,000 and an EBITDA of -$97,469,000. The substantial gap between positive revenue and negative net income reveals a heavy cost structure where operating expenses significantly erode profitability, a common characteristic in the early growth phases of medical device manufacturing. Free cash flow stands at -$23,916,124, indicating that current cash generation is insufficient to cover operational burn, which implies limited financial flexibility for expansion without external capital infusion or existing reserves. The gross margin is reported at 63.7%, suggesting efficient production and pricing power, whereas the operating margin is -40.6% and the profit margin is -31.0%, highlighting that high overhead costs are currently outweighing gross profits. On the balance sheet, the company holds $286.50 million in cash against $78.48 million in debt, resulting in a debt-to-equity ratio of 21.45 which suggests a leveraged capital structure relative to equity. Despite the leverage, the current ratio of 6.84 indicates robust short-term liquidity, as the firm possesses more than six times the current assets required to meet its short-term obligations. Return on Equity is -24.9% and Return on Assets is -12.5%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns.
Evaluación de valoración
The trailing P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is -28.32, implying that the market prices the stock based on future earnings expectations rather than current profitability. The price-to-book ratio is 3.85, which indicates that the market is valuing the company at a significant premium above its net book value, reflecting expectations of future growth potential rather than current asset value. Alternative valuation metrics include a price-to-sales ratio of 4.58 and an EV/EBITDA of -12.34, suggesting that investors are prioritizing revenue expansion over immediate earnings quality in their valuation models. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $66.85 and a 52-week low of $19.35. If the current price is assumed to be near the lower end of the range given the negative earnings metrics, the stock would be trading at approximately 71% below the 52-week high, reflecting a substantial correction from peak valuations. The beta value is 1.02, indicating that the stock's price volatility moves in tandem with the broader market, presenting slightly higher sensitivity than the overall index.
Growth & Income
Revenue growth year-over-year is recorded at 11.9%, while earnings growth is N/A due to the company's current unprofitable status. Since there are no earnings to compare directly, the revenue expansion suggests top-line growth is the primary driver of company performance, with profitability trailing behind sales momentum. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available cash flow back into research, development, and operational scaling rather than distributing income to shareholders. This reinvestment strategy is typical for surgical robotics firms seeking to capture market share and refine their AquaBeam technology before achieving sustained profitability. The overall growth and income profile is characterized by double-digit revenue expansion coupled with a complete absence of dividend income, positioning the asset as a pure growth vehicle for investors seeking exposure to the medical robotics sector.